^
    6ms
    A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=61, Completed, MedImmune LLC | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Imfinzi (durvalumab) • MEDI1191
    over1year
    A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, MedImmune LLC | Recruiting --> Active, not recruiting | N=102 --> 61 | Trial completion date: Sep 2027 --> Aug 2023 | Trial primary completion date: Sep 2027 --> Aug 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Imfinzi (durvalumab) • MEDI1191
    almost2years
    A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=102, Recruiting, MedImmune LLC | Trial completion date: Jan 2027 --> Sep 2027 | Trial primary completion date: Jan 2027 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Imfinzi (durvalumab) • MEDI1191
    2years
    First-in-human study of MEDI1191 (mRNA encoding IL-12) plus durvalumab in patients (pts) with advanced solid tumors (AACR 2022)
    IT MEDI1191 plus systemic anti-PD-L1 was safe and feasible. Preliminary antitumor efficacy and pharmacodynamics, including tumor CD8+ T cell recruitment, were consistent with expected mechanism of action. Pts with injectable deep visceral and superficial lesions are being recruited.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • MEDI1191
    over2years
    A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=87, Recruiting, MedImmune LLC | Trial completion date: Oct 2027 --> Jan 2027 | Trial primary completion date: Oct 2027 --> Jan 2027
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Imfinzi (durvalumab) • MEDI1191
    3years
    [VIRTUAL] Preliminary safety, antitumor activity and pharmacodynamics results of HIT-IT MEDI1191 (mRNA IL-12) in patients with advanced solid tumors and superficial lesions (TAT 2021)
    Clinical trial identification NCT03946800. Conclusions Sequential combination of IT MEDI119 with IV durvalumab was well tolerated and showed encouraging preliminary antitumor and pharmacodynamic activity including in IO pre-treated pts, consistent with the expected mechanism of action. The study is active and recruiting.
    Clinical • PK/PD data
    |
    IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
    |
    PD-L1 negative
    |
    Imfinzi (durvalumab) • MEDI1191
    over3years
    A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=79, Recruiting, MedImmune LLC | Trial completion date: Nov 2026 --> Sep 2027 | Trial primary completion date: Nov 2026 --> Sep 2027
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Imfinzi (durvalumab) • MEDI1191
    almost4years
    [VIRTUAL] MEDI1191, a novel IL-12 mRNA therapy for intratumoral (IT) injection for advanced solid tumours (ESMO 2020)
    Trial design This phase I, multicenter, open-label, dose-escalation (Part 1) and expansion (Part 2) study (NCT03946800) evaluates the safety and efficacy of MEDI1191 IT in sequential or concurrent combination with durvalumab 1500 mg Q4W IV. Funding: AstraZeneca. Clinical trial identification: NCT03946800.
    PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    Imfinzi (durvalumab) • MEDI1191
    almost4years
    A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=79, Recruiting, MedImmune LLC | Trial completion date: Dec 2027 --> Nov 2026 | Trial primary completion date: Dec 2027 --> Nov 2026
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Imfinzi (durvalumab) • MEDI1191
    almost4years
    A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=87, Recruiting, MedImmune LLC | Active, not recruiting --> Recruiting | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Dec 2027
    Clinical • Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Imfinzi (durvalumab) • MEDI1191